Pharm

Idarucizumab

search

Idarucizumab, Praxbind

  • See Also
  1. Dabigatran (Pradaxa)
  2. Emergent Reversal of Anticoagulation
  3. Hemorrhagic Shock
  • Mechanism
  1. Anticoagulation Reversal agent
  2. Monoclonal Antibody specifically binds Dabigatran
  • Pharmacokinetics
  1. Half-Life: 1 hour
  2. Renally excreted
  • Efficacy
  1. Idarucizumab is highly effective (100%) in initial studies and FDA approval
  2. Complete Dabigatran reversal within minutes with effect lasting >24 hours, without Hypercoagulable adverse effects
  • Dosing
  1. Idarucizumab 5 gram IV
  • Disadvantages
  1. Expensive ($3500 wholesale in 2016)
  • Adverse Effects
  1. Thrombosis risk 6% at 30 days
  2. Mild adverse effects (Headache, skin and infusion site irritation)
  • References
  1. Gartland and Abboud (2020) Crit Dec Emerg Med 34(1):18
  2. Buchheit (2016) Crit Pathw Cardiol 15(3):77-81 [PubMed]
  3. Pollack (2015) N Engl J Med 373(6): 511-20 +PMID: 26095746 [PubMed]
  4. Pollack (2017) N Engl J Med 377(5): 431-41 +PMID:28693366 [PubMed]